Context Therapeutics closed at $0.20 on Nov 4, up 4.90%, 93.9% below its 52-week closing high. Volume of 8.3M shares was 7.29× its 20-day average (well above normal).
Split-adjusted performance: -36.8% over one month, -91.6% over six months, -81.2% over one year.
Short interest was 4.3M shares at the Oct 15 settlement, down 9.2% from the prior report (6.2% of float, 5.1 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CNTXContext Therapeutics | $0.2035 | +4.90% | −91.6% | — | — | — | $18.7M | |
| COCPCocrystal Pharma | $1.01 | −5.61% | −28.4% | — | −3013.3% | — | $19.5M | Compare |
| KTTAPasithea Therapeutics | $0.5300 | 0.00% | −37.6% | — | — | — | $17.7M | Compare |
| IGCIGC Pharma | $0.1950 | +4.84% | −38.7% | −19.2% | −1107.9% | — | $20.2M | Compare |
| ALLRAllarity Therapeutics | $1.08 | −4.42% | −27.0% | — | — | — | $17.2M | Compare |
| MRKRMarker Therapeutics | $1.01 | +2.76% | −30.8% | — | — | — | $16.8M | Compare |
| AYTUAYTU BioPharma | $1.92 | −0.52% | −25.0% | +6.4% | −0.1% | — | $20.9M | Compare |
| EDSAEdesa Biotech | $2.17 | −4.82% | −85.5% | — | — | — | $20.9M | Compare |
| MTEXMannatech | $8.64 | −0.06% | +77.0% | +3.8% | 3.8% | — | $16.7M | Compare |
No recent articles focused on Context Therapeutics. 2 articles mention it in passing.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
